The dominant theory in economics for centuries in the Western world has been the free market system, yet the ability of competitive markets to provide quality care has been a central point of recent debate. Extensive government regulation, though well-intentioned, adversely affects the overall health of Americans, inhibits medical innovation, and demands enormous tax-payer investment. The Initiative on Enabling Choice and Competition in Healthcare delivers cutting edge research on the efficiencies of competitiveness in the healthcare sector to demonstrate that free market forces can and do work to provide innovative, equitable, and high-quality care.
Our Vision
To be the leading university-based research center in free-market healthcare, promoting choice and competition to ensure greater access to existing care and new innovations.
Our Mission
To conduct evidence-based research and analyses on market-based choice and competition in the healthcare sector to lead to better-informed policy recommendations.
Working Papers
Issue Brief: The Impact of HR 5376 on Biopharmaceutical Innovation and Patient Health
This issue brief reviews the evidence-base to assess the impact of HR 5376 on drug innovation and patient health. A large academic literature estimates the effect of future drug revenues on R&D spending and finds that on average that a 1 percent reduction in...
Issue Brief: The Impact of HR 5376 on Antiviral Innovation and Patient Health
This issue brief reviews the evidence-base to assess the impact HR 5376 on innovation into antivirals and patient health. A large academic literature estimates the effect of future drug revenues on R&D spending and finds that on average that a 1 percent reduction...
Issue Brief: The Evidence Base on The Impact of Price Controls on Medical Innovation
This issue brief reviews the evidence on the impact of price controls on biopharmaceutical innovation and calibrates what this evidence implies for recent price control proposals in the US. A large academic literature estimates the effect of future drug revenues on...
Learn more about Operation Warp Speed:
In the Press
Ending Pay for PBM Performance: Consequences for Prescription Drug Prices, Utilization, and Government Spending | September 2023
Proposed “delinking” legislation would prohibit Pharmacy Benefit Managers (PBMs) from being remunerated based on the rebates and discounts they...
Policy Brief: The Potentially Larger Than Predicted Impact of the IRA on Small Molecule R&D and Patient Health | August 2023
This policy brief analyzes the impact of regulatory and legislative changes within the Inflation Reduction Act (IRA) on medical R&D and patient...
The Value of Medical Innovation in the Fight Against COVID-19 in the United States | August 2023
A longstanding economic literature argues that the total welfare loss of a disease comes not only from the direct effects of the disease itself, but...
2024 ECCHC Supply-Side Economics in Healthcare Conference – Watch Now!
The 2024 ECCHC Supply-side Economics in Healthcare Conference convened both in-person and virtually on Friday, May 3. Watch the full conference, or individual presentations and learn more about the conference here!